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A Novel Role for Lymphotactin (XCL1) Signaling in the Nervous
System: XCL1 Acts via its Receptor XCR1 to Increase Trigeminal
Neuronal Excitability
Emma V. Bird, a§ Tommaso Iannitti, by§ Claire R. Christmas, a§ Ilona Obara, b Veselin I. Andreev, a– Anne E. King b* and
Fiona M. Boissonade a*
aSchool of Clinical Dentistry, University of Sheffield, Sheffield S10 2TA, UK
bSchool of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK
Abstract—Chemokines are known to have a role in the nervous system, influencing a range of processes includ-
ing the development of chronic pain. To date there are very few studies describing the functions of the chemokine
lymphotactin (XCL1) or its receptor (XCR1) in the nervous system. We investigated the role of the XCL1-XCR1 axis
in nociceptive processing, using a combination of immunohistochemical, pharmacological and electrophysiolog-
ical techniques. Expression of XCR1 in the rat mental nerve was elevated 3 days following chronic constriction
injury (CCI), compared with 11 days post-CCI and sham controls. XCR1 co-existed with neuronal marker
PGP9.5, leukocyte common antigen CD45 and Schwann cell marker S-100. In the trigeminal root and white matter
of the brainstem, XCR1-positive cells co-expressed the oligodendrocyte marker Olig2. In trigeminal subnucleus
caudalis (Vc), XCR1 immunoreactivity was present in the outer laminae and was colocalized with vesicular gluta-
mate transporter 2 (VGlut2), but not calcitonin gene-related peptide (CGRP) or isolectin B4 (IB4). Incubation of
brainstem slices with XCL1 induced activation of c-Fos, ERK and p38 in the superficial layers of Vc, and enhanced
levels of intrinsic excitability. These effects were blocked by the XCR1 antagonist viral CC chemokine macro-
phage inhibitory protein-II (vMIP-II). This study has identified for the first time a role for XCL1-XCR1 in nociceptive
processing, demonstrating upregulation of XCR1 at nerve injury sites and identifying XCL1 as a modulator of cen-
tral excitability and signaling via XCR1 in Vc, a key area for modulation of orofacial pain, thus indicating XCR1 as a
potential target for novel analgesics.  2018 The Authors. Published by Elsevier Ltd on behalf of IBRO. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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INTRODUCTION
Chemokines are a large family of small, secreted proteins
divided into four subgroups – CXC, CC, C and CX3C –
according to the number and positioning of the highly
conserved cysteine residues in their amino acid
sequence (White et al., 2005). They exert their biological
effects by binding to cell surface receptors belonging to
the G-protein-coupled receptor superfamily, the receptor
classes being designated CXCRn, CCRn, XCRn and
CX3CRn (Kufareva et al., 2015). Chemokines have a
well-established role regulating the migration of leuko-
cytes and coordinating inflammatory responses. An
increasing number of studies have demonstrated an
important role for chemokine signaling in the nervous sys-
tem (Roste`ne et al., 2007), where they have diverse
effects in a range of physiological and pathological pro-
cesses, regulating neuronal development, neuroinflam-
mation and synaptic transmission. Consequently, they
have been implicated in a variety of neurological disorders
including multiple sclerosis, Parkinson’s, Huntingdon’s
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and Alzheimer’s diseases (Mines et al., 2007; Hamann
et al., 2008; Wild et al., 2011; Cheng and Chen, 2014;
Savarin-Vuaillat and Ransohoff, 2007). Some chemoki-
nes have also been shown to be critical in the develop-
ment and maintenance of chronic pain, via their roles in
altered excitability and nociceptive processing (Grace
et al., 2014; Me´lik Parsadaniantz et al., 2015; Tsuda,
2017). Chronic pain, including that from the orofacial
region, represents a major health issue, impacting on
health and quality of life, and on economic and employ-
ment issues (Phillips and Harper, 2011; Patel et al.,
2012; Duen˜as et al., 2016; Rice et al., 2016). Despite
improved knowledge of mechanisms underlying pain,
there are still considerable gaps in our understanding of
chronic pain – including neuropathic pain – occurring as
a consequence of pathology or injury affecting the ner-
vous system. Treatment for this type of pain is limited
and often ineffective (Rice et al., 2016). As outlined
above, some chemokines act as neuromodulators within
the nervous system, where they are expressed by both
glia and neurons (Miller et al., 2009; Old and Malcangio,
2012), and thus may provide novel potential therapeutic
targets for chronic pain.
Lymphotactin (XCL1) – a member of the least
examined C class of chemokines (Kelner et al., 1994) –
is produced by subsets of T cells and natural killer cells
in response to infection and inflammation, and is chemo-
tactic for T lymphocytes through binding to its receptor
(XCR1) (Huang et al., 2001; Dorner et al., 2002; Lei and
Takahama, 2012). Initial studies indicated expression of
XCR1 within a range of immune cells, however more
recent work indicates that it is selectively expressed in
subsets of dendritic cells (reviewed in Lei and
Takahama, 2012). Increased levels of XCL1 and XCR1
have been reported in joint fluid of rheumatoid arthritis
patients (Wang et al., 2004), and XCL1 is also present
in oral mucosal endothelial cells in oral cancer (Khurram
et al., 2010; Kiaii et al., 2013), suggesting that XCL1
may be present in other cell types and is upregulated in
disease conditions. Other reports demonstrate involve-
ment of XCL1-XCR1 in Crohn’s disease (Middel et al.,
2001) and in suppression of HIV-1 infection (Guzzo
et al., 2013). There is little evidence to date for the pres-
ence of XCL1-XCR1 in the nervous system or of its poten-
tial role in nociceptive processing. Therefore the overall
aims of this study were to investigate the role of lympho-
tactin and its receptor in hyperexcitability and signaling,
and establish their potential contribution to the develop-
ment of orofacial neuropathic pain.
In this study we used immunohistochemistry to
examine which components of the orofacial pain
pathway express XCR1. Specifically, we determined the
expression of XCR1 in specific cell types at the site of a
trigeminal nerve injury and in the trigeminal subnucleus
caudalis (Vc), a region of the brainstem involved in the
central processing of orofacial pain. Using a
combination of pharmacological and electrophysiological
studies, we investigated the novel role for XCL1-XCR1
axis in the modulation of increased neuronal activity and
altered intracellular signaling (specifically c-Fos, pERK,
pp38) within Vc, and determined the potential
contribution of this axis to the development of trigeminal
neuropathic pain.
EXPERIMENTAL PROCEDURES
Animals
A total of 47 rats were used in the study: 22 male
Sprague–Dawley rats (age 7–9 weeks; 225–250 g);
6 female Wistar rats (age 3–5 weeks; 70–80 g); 3 male
Wistar rats (age 7–9 weeks; 200–250 g); and 16 male
Wistar rats (age 3–5 weeks; 70–80 g). Details of animal
use for different elements of the study are described in
the relevant sections below; in all cases animal numbers
were based on power calculations using data from
previous studies that employed similar protocols. All
animals were obtained from Harlan Laboratories Ltd
(Bicester, UK). They were allowed to acclimatize to the
colony room (Biological Services, University of Sheffield
or Central Biological Services, University of Leeds) for
at least 7 days after arrival and were housed in
polyethylene cages (4 per cage), controlled for
temperature (21 C) and humidity (55%) under a regular
12-h light/dark cycle (lights on 08:00; lights off 20:00).
Standard laboratory rodent chow and water were
available ad libitum. All efforts were made to minimize
animal suffering and to reduce the number of animals
used in the study. Experimental protocols were
performed under appropriate UK Home Office Licences,
with local ethical approval, and in accordance with
current UK legislation as defined in the Animals
(Scientific Procedures) Act 1986. The ARRIVE
guidelines (Kilkenny et al., 2010) have been followed in
reporting this study.
Characterization of XCR1 expression in the
trigeminal system
Mental nerve injury. Adult male Sprague–Dawley rats
(n= 16; 225–250 g) received a chronic constriction injury
(n= 8, CCI) to the mental nerve or a sham procedure (n
= 8, Sham). The CCI procedure has been described
previously in studies carried out in our laboratories (Bird
et al., 2002; Evans et al., 2014), and the techniques used
were in keeping with Bennett and Xie’s original descrip-
tion of the CCI (Bennett and Xie, 1988). Under general
anesthesia (isoflurane; 4% induction and 2–3% mainte-
nance) the left mental nerve was exposed and constricted
with two loosely tied 6/0 chromic catgut sutures (Ethicon,
Norderstedt, Germany), with a spacing of 1 mm between
the sutures. In the Sham group the mental nerve was
exposed, but no constriction performed. In all animals
the subcutaneous tissue and overlying skin were closed
with 4/0 vicryl sutures (Ethicon). The animals were left
to recover for periods of 3 or 11 days (n= 8 [4 CCI, 4
Sham] per recovery period). Naı¨ve adult male Sprague–
Dawley rats were also used as unoperated controls
(n= 4; 225–250 g).
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Tissue collection. At the end of the recovery period
rats were deeply anesthetized with pentobarbital
(500 mg/kg, i.p.; J M Loveridge Ltd, Andover, UK) and
perfused transcardially with 500 ml phosphate-buffered
saline (PBS), followed by 500 ml 4% paraformaldehyde
(PFA) fixative. Right and left mental nerves and
trigeminal ganglia, and brainstems were removed, post-
fixed in 4% PFA for 4 h and cryoprotected in 30%
sucrose overnight, both at 4 C. A small groove was
made along the ventral surface of the brainstem to allow
identification of the left and right sides. All the tissues
were then embedded (brainstem transversely, ganglia
and nerves longitudinally) in Tissue-Tek OCT compound
(Sakura Finetek, Alphen aan den Rijn, Netherlands) and
stored at 80 C. Frozen serial brainstem sections
(30 mm) were sectioned on a microtome cryostat
(Microm HM560; Thermo Scientific, Walldorf, Germany),
from 5 mm caudal to 10 mm rostral to obex (the point at
which the central canal opens up into the fourth
ventricle) and collected free-floating in 24-well plates.
Mental nerves and trigeminal ganglia were serially
sectioned at 14 mm and thaw-mounted onto poly D-lysine
(Sigma–Aldrich Company Ltd, Gillingham, Dorset, UK)-
coated glass microscope slides.
Immunohistochemistry. Free-floating brainstem
sections, and nerve and ganglia slides were blocked in
PBS containing 0.5% Triton X-100 (PBST) and 20%
normal donkey serum (NDS; Jackson ImmunoResearch
Labs Cat# 017-000-001; RRID:AB_2337254; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA,
USA) for 1 h at room temperature and then incubated
overnight at 4 C with rabbit anti-XCR1 primary antibody
(1:500; LifeSpan Cat# LS-A158-50; RRID:AB_1116636;
LifeSpan Biosciences, Inc., Seattle, WA, USA) diluted in
PBST and 5% NDS. They were then incubated for
90 min at room temperature with donkey anti-rabbit
secondary antibody conjugated to indocarbocyanine
(Cy3) (1:500; Jackson ImmunoResearch Labs Cat#
711-165-152; RRID:AB_2307443; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA,
USA) diluted in PBST containing 1.5% NDS. If no
further labeling was required (i.e. XCR1 alone), tissue
was mounted and coverslipped using fluorescence-free
Vectashield medium (Vector Laboratories, Burlingame,
CA, USA). For double-labeling studies, tissue was then
incubated overnight at 4 C with antibodies raised in
mouse to Olig2 (1:200; R and D Systems Cat#
BAF2418; RRID:AB_2251803; R&D Systems,
Minneapolis, MN, USA), calcitonin gene-related peptide
(CGRP) (1:250; Sigma–Aldrich Cat# C7113; RRID:AB_
259000; Sigma–Aldrich, St. Louis, MO, USA), CD45
(1:2000; AbD Serotec Cat# MCA43GA; RRID:AB_
566759; Bio-Rad, Oxford, UK), S-100 (1:100; Millipore
Cat# MAB079-1; RRID:AB_571112; Merck Millipore,
Watford, UK) or PGP 9.5 (1:1000; UltraClone Cat#
RA95101; RRID:AB_2313685; UltraClone, Histon,
Cambridge, UK) or with isolectin B4 (IB4) (1:4000;
Molecular Probes Cat# I21411; RRID:AB_2314662;
Thermo Fischer Scientific, Waltham, MA, USA); diluted
in PBST and 5% NDS. The sections were next
incubated with a donkey anti-mouse secondary
antibody, conjugated to fluorescein isothiocyanate
(FITC) (1:300; Jackson ImmunoResearch Labs Cat#
715-095-150; RRID:AB_2340792i; Jackson
ImmunoResearch Laboratories Inc., West Grove, PA,
USA) diluted in PBST containing 1.5% NDS for 90 min
at room temperature prior to being mounted and
coverslipped as described above. Immunohistochemical
controls for XCR1 were performed by liquid-phase
preabsorption of the primary antibody with its respective
ligand (10 nmol/ml). Images were acquired with a Zeiss
Axioplan 2 imaging fluorescence microscope, fitted with
a HBO 50 mercury lamp. Image acquisition and
processing were performed with Image Pro-Plus (v5.1,
Media Cybernetics, Rockville, MD, USA). For
quantitative analysis of the constricted nerves, the
specimen was divided into three regions (proximal,
middle and distal; Fig. 1B) and the percentage area of
positive immunofluorescence within the nerve was
calculated for each region. The percentage area of
positive immunofluorescence within the proximal and
distal sections of the nerve was calculated over a
distance of 500 mm from the most proximal or distal
suture. Quantification was undertaken of a single
section in each animal; analysis was carried out blind to
the recovery period (i.e., 3 or 11 days) following CCI.
Confocal images were obtained using a Nikon A1
confocal microscope.
XCR1 and glutamatergic synaptic terminals. In an
additional group of animals XCR1 in the spinal
trigeminal subnucleus caudalis (Vc) was localized with
the markers of glutamatergic synaptic terminals
vesicular glutamate transporter 1 and 2 (VGlut1 and
VGlut2, respectively). Naı¨ve adult male Wistar rats
(n= 3; 200–250 g) were deeply anesthetized and
perfused transcardially with PFA. The brainstems were
dissected out, post-fixed in the same PFA solution for 2
h at 4 C and transferred into PBS containing 0.01%
azide for a minimum of 24 h. Serial 50-lm transverse
brainstem sections were incubated for 72 h at 4 C in
PBS containing rabbit anti-XCR1 (1:250; Abcam Cat#
ab67342; RRID:AB_2217066; Abcam, Cambridge, UK)
and guinea-pig anti-VGlut1 (1:2500; Millipore Cat#
AB5905; RRID:AB_2301751; Merck Millipore, Germany)
or guinea-pig anti-VGlut2 (1:5000; Millipore Cat#
AB2251; RRID:AB_1587626; Merck Millipore, Germany)
antibodies. Appropriate direct secondary antibodies
were applied, sections were mounted with Gel Mount
aqueous mounting medium (Sigma–Aldrich, UK) and
visualized using a fluorescence microscope. Images
were captured using an inverted confocal microscope
(LSM 700; Carl Zeiss Microscopy, USA) in conjunction
with Zen 2.1 (Black) software (Carl Zeiss Microscopy,
USA).
Reverse transcriptase–polymerase chain reaction
(RT–PCR). To determine the expression of rat XCR1
mRNA, adult male Sprague–Dawley rats (n= 2; 225–
250 g) underwent mental nerve CCI as described
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above, and after 3 days were culled by pentobarbital (500
mg/kg, i.p.; J M Loveridge Ltd, UK). The right and left
mental nerves and brainstem were removed and stored
at 80 C. Total RNA was isolated from rat mental
nerve and brainstem using TRI REAGENT (Sigma–
Aldrich, USA) following the manufacturer’s instructions.
Proximal (4) Middle (4) Distal (4)
0
2000
4000
6000
8000
10000
Region of constricted mental nerve
M
e
a
n
 a
re
a
 o
f 
im
m
u
n
o
re
a
c
ti
v
it
y
 (
µ m
2
)
*
Sham 3d (4) 3d (4) Sham 11d (4) 11d (4)
0
1000
2000
3000
4000
5000
Recovery periods following CCI
M
e
a
n
 a
re
a
 o
f 
im
m
u
n
o
re
a
c
ti
v
it
y
 (
µm
2
) ***
Fig. 1. XCR1 is not expressed in naı¨ve or sham-operated rat mental nerve, however it is present following peripheral nerve injury. (A) XCR1
immunofluorescent labeling in rat mental nerve, 3 days (3 d) following chronic constriction injury (CCI) to the nerve (far left and center left) and in an
uninjured nerve (naı¨ve, center right), and following preabsorption of the XCR1 primary antibody with its respective hapten. Scale bars = 100 lm.
(B) Montage of photomicrographs showing XCR1 expression in the three distinct regions of the mental nerve, 3 days after CCI. The bright red
circular structures at the proximal end are the sutures used to perform the CCI. Scale bar = 100 lm. (C) XCR1 immunofluorescent expression
appeared to be more abundant 3 days following CCI (3 d) compared with 11 days after injury (11 d) and in sham control mental nerve. Scale bars =
100 lm. (D) Levels of XCR1 fluorescent immunoreactivity were significantly higher in the middle region of the constricted nerve 3 days after CCI
compared with the proximal and distal regions (left panel, p< 0.05). XCR1 immunoreactivity was higher in 3 days post-injury nerves, compared with
11 days post-injury nerves (right panel, p< 0.0001); after 3 days, XCR1 labeling was also significantly higher in the CCI group than in the Sham
group (no labeling) (p< 0.0001). Data are expressed as the mean ± SEM; statistical analysis by ANOVA with post-hoc Tukey’s multiple
comparisons test. Note that the second panel of (C) is a higher magnification image of the same section shown in the first panel of (A).
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GAPDH was used as the housekeeping gene. The cDNA
was amplified using the following primer sequences:
XCR1: sense AGCTGGGGTCCCTACAACTT, anti-
sense GACCCCCACGAAGACATAGA;
GAPDH: sense AAATGGTGAAGGTCGGTGTGAAC,
anti-sense CAACAATCTCCACTTTGCCAC.
The PCR cycles were performed at 94 C for 1 min,
annealing at 60 C for 2 min and extension at 72 C for
3 min for a total of 35 cycles. A 1% agarose gel
containing ethidium bromide was used to separate the
PCR fragments and the gel was visualized and
photographed using an imaging system (Syngene,
Cambridge, UK).
Assessment of c-Fos, pERK and pp38 activation
following application of XCL1
In vitro activation of c-Fos, pERK and pp38. In order to
identify the effect of XCL1 and its antagonist viral CC
chemokine macrophage inhibitory protein-II (vMIP-II;
Shan et al., 2000) on the activity of c-Fos, pERK and
pp38, naı¨ve male Wistar rats (n= 16; 70–80 g) were irre-
versibly anesthetized with pentobarbital (40–50 mg/kg,
i.p.; Sigma–Aldrich, UK) and then received 0.1 ml Lignol
(2.0% lignocaine w/v with adrenalin; Dechra Veterinary
Products Ltd, UK) s.c. into the neck scruff at the base of
the skull to reduce incisional sensory activation. The rats
were then perfused transcardially with ice-cold hep-
arinized (0.1%) artificial cerebrospinal fluid (aCSF; in
mM: NaCl, 128; KCl, 1.9; KH2PO4, 1.2; MgSO4, 1.3;
CaCl2, 2.4; NaHCO3, 26; glucose, 10; pH 7.4) and the
brainstem was removed, dissected free of meninges
and placed into a plastic holding chamber containing
aCSF maintained at a constant 37 C using a water bath.
The tissue was left to rest for 2 h in aCSF containing the
sodium channel blocker tetrodotoxin (TTX) (1 lM; Tocris-
Cookson, Bristol, UK) added to prevent non-specific
neuronal activation and indirect conducted excitation.
Brainstems were maintained for an additional 2 h in aCSF
containing TTX plus XCL1 (0.1 mM; n= 4), vMIP-II
(0.1 mM; n= 4), or XCL1 (0.1 mM) plus vMIP-II (0.1 mM;
n= 4). Controls (n= 4) were incubated in aCSF and
TTX only. The tissue was then retained in aCSF
containing TTX for 1 h, before fixation overnight in 4%
PFA prior to processing for immunohistochemistry.
Immunohistochemistry. Tissue was cut into serial 50-
lm transverse sections, between obex and 1600 mm
caudal to obex, using a vibratome (Leica Microsystems,
Wetzlar, Germany). Sections were blocked in 0.1%
PBST containing 10% NDS for 1 h at room temperature
and then incubated in one of: rabbit anti-pp38 (1:300;
Cell Signaling Technology Cat# 9211; RRID:AB_
331641; Cell Signaling Technology, Danvers, MA, USA);
rabbit anti-pERK (1:500; Cell Signaling Technology Cat#
4370; RRID:AB_2315112; Cell Signaling Technology,
Danvers, MA, USA); or goat anti c-Fos (1:1000; Santa
Cruz Biotechnology Cat# sc-52-G; RRID:AB_2629503;
Santa Cruz Biotechnology Inc., Dallas, TX, USA) diluted
in 0.1% PBST and 5% NDS overnight at 4 C or room
temperature. Sections were next incubated with
appropriate secondary antibodies (1:1000) for 2 h,
mounted with Vectashield mounting medium (Vector
Laboratories, CA, USA) and cover-slipped. For dual-
labeling studies, brainstem sections were incubated
overnight with antibodies to the neuronal marker NeuN
(rabbit anti-NeuN, 1:1000; Millipore Cat# MAB377;
RRID:AB_2298772; Millipore, Billerica, MA, USA), the
microglial marker ionized calcium-binding adapter
molecule 1 (Iba1) (goat anti-Iba1, 1:500; Abcam Cat#
ab5076; RRID:AB_2224402; Abcam, Cambridge, UK),
or the astrocyte marker glial fibrillary acidic protein
(GFAP) (mouse anti-GFAP, 1:1000; Millipore Cat#
IF03L; RRID:AB_212974; Merck Millipore, Watford, UK),
and then with appropriate secondary antibody. Controls
included omission of the primary or secondary
antibodies. Immunolabeling was visualized using an
inverted confocal microscope (LSM 700; Carl Zeiss
Microscopy, USA) in conjunction with Zen 2.1 (Black)
software (Carl Zeiss Microscopy, USA). For semi-
quantification of pp38 expression levels, the mean
intensity of staining from a fixed-size region of Vc
visualized at low magnification (10) was calculated
using ImageJ software and plotted as a total mean ±
standard error of the mean (SEM) value calculated
across a portion of Vc running from obex to 1600 lm
caudal to obex (eight sections per animal at 200-lm
intervals throughout Vc). For quantification of c-Fos and
pERK, positive nuclei within the trigeminal subnucleus
caudalis were counted from obex to 1600 lm caudal to
obex (eight sections per animal at 200-lm intervals
throughout Vc). Sections were counted blind by the
same investigator.
Electrophysiology. Female Wistar rats (n= 6; 65–75
g) were deeply anesthetized and perfused transcardially
with ice-cold aCSF containing sucrose. The brainstem
was removed quickly and placed in oxygenated
(95% O2/5% CO2) ice-cold standard aCSF to remove
meninges. The brainstem was trimmed rostrocaudally to
isolate an area 2–3 mm caudal to obex (including Vc)
and embedded in 3% agar solution (Alfa Aesar,
Haverhill, MA, USA). Transverse brainstem slices (350
mm) were cut using a vibratome (Leica VT1000S, Leica
Microsystems, Germany) and placed into ice-cold,
oxygenated aCSF. Slices were transferred to a holding
chamber, where they were submerged in oxygenated
aCSF maintained at 35 C and incubated for 1 h. The
slices were then incubated for 2 h with one of the
following, diluted in aCSF: mouse recombinant XCL1
(0.1 mM; Sigma–Aldrich, UK); XCL1 antagonist vMIP-II
(0.1 mM; R&D Systems, Minneapolis, MN, USA); normal
aCSF; or vMIP-II (0.1 mM) plus XCL1 (0.1 mM) prior to
the electrophysiological recordings.
For recordings, brainstem slices were transferred to a
custom-built Perspex chamber that maintained tissue in
an interface between a warm (32 C), humidified
carbogen (95% O2/5% CO2) environment and aCSF at
an average flow rate of 1–1.5 ml/min. Extracellular field
recordings of baseline and drug-induced subthreshold
rhythmic activity were made using borosilicate
glass microelectrodes (Harvard Apparatus, Kent, UK;
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10–20 MX) filled with normal aCSF and placed at a depth
of 15 mm into the superficial laminae of trigeminal Vc.
Voltage waveforms were recorded and amplified (10)
by an Axoclamp 2A system (Molecular Devices, CA,
USA), with further amplification (1000) provided by a
Neurolog NL106 module (Digitimer, Welwyn Garden
City, UK). The voltage signals in all experiments were
filtered using a low-pass band filter setting of 40 Hz
(Neurolog NL125; Digitimer). Voltage waveforms were
digitized at 5 kHz and captured for further analysis with
Spike 2 software (Cambridge Electronic Design,
Cambridge, UK). To extract characteristics of
subthreshold low-amplitude voltage oscillations, power
spectra were generated using 1-second epochs and the
amplitude of the peak frequency measured to give the
power of the oscillation. Power amplitude (measured as
maximum peak height in spectra) and area values
(calculated as the area under the curve for two cursors
set at 4 and 12 Hz in spectra) were derived from an
average of five consecutive 1-second epochs. The
sampling rate was 5 kHz, which was divided by the
8192 points in the fast Fourier transform, to provide an
overall resolution of 0.6 Hz.
Statistical analysis
Data analysis and statistical comparisons were performed
using GraphPad Prism (version 5.0d; RRID:SCR_
002798; GraphPad Software, Inc., La Jolla, CA, USA).
Analysis of variance (ANOVA) with a post-hoc Tukey’s
multiple comparisons test was performed to assess the
difference in the level of XCR1 expression at the injury
site between experimental groups. A one-way ANOVA
with Dunnett’s post-hoc test was used to analyze
parameters of power amplitude and power area and
levels of c-Fos, pERK and pp38. Data values are
expressed as the mean ± SEM. Values of p< 0.05
were considered statistically significant.
RESULTS
XCR1 is expressed in the peripheral nervous system
Immunohistochemical labeling for XCR1 was present in
the rat mental nerve 3 days following CCI (Fig. 1); no
labeling was present in the mental nerves of sham-
operated or naı¨ve animals. Two types of XCR1 labeling
were observed in the injured mental nerve: beaded
fiber-like staining indicative of labeling within a nerve
fiber, and irregular dense punctate labeling (Fig. 1A). At
3 days post injury, immunoreactive labeling for XCR1
was present in the proximal, middle and distal regions of
the constricted nerve (Fig. 1B): quantitative image
analysis revealed significantly higher levels of XCR1
immunoreactivity in the middle region of the constricted
mental nerve (6050 ± 2292 mm2 [SEM]), compared
with the proximal (2033 ± 453 mm2) and distal (282 ±
153 mm2) regions (p< 0.05; Fig. 1D). Levels of
XCR1 labeling appeared higher 3 days after CCI,
compared with 11 days after (Fig. 1C), with quantitative
analysis revealing a statistically significant difference
between the two recovery periods (2788 ± 567 mm2
[3 days] vs 218 ± 135 mm2 [11 days]: p< 0.0001;
Fig. 1D). The quantity of XCR1 labeling after 3 days
was significantly higher in the CCI group than in
the Sham group (no labeling) (p< 0.0001). Positive
XCR1 labeling was abolished following liquid-phase
pre-absorption of the antibody with its respective antigen,
indicating specificity of the XCR1 antibody (Fig. 1A).
The time course of increased XCR1 expression seen
here correlates with the development of spontaneous
activity at sites of trigeminal nerve injury (Bongenhielm
and Robinson, 1996, 1998; Yates et al., 2000).
As illustrated in Fig. 2A, dual labeling of the mental
nerve for XCR1 and the neuronal marker PGP9.5
revealed that while a proportion of XCR1 labeling was
co-localized within PGP9.5-labeled nerve fibers, there
was a substantial proportion that was not. Further
labeling of the mental nerve with the leukocyte common
antigen CD45 (Fig. 2B) and Schwann cell marker S-100
(Fig. 2C) indicated that XCR1 also showed some
degree of co-localization with these two cell types.
In addition, quantitative RT–PCR analysis of tissue
collected from rats 3 days following CCI revealed that
the level of XCR1 mRNA in the injured (left) mental
nerve was much higher when compared with the
uninjured (right) side, where mRNA was barely
detectable (Fig. 2D). XCR1 mRNA was also detected in
the brainstem of CCI rats (Fig. 2D).
XCR1 is expressed in the central nervous system
A population of XCR1-positive cells was observed in a
region of the trigeminal root, central to the transition
zone (the boundary between the peripheral and central
nervous systems) (Fig. 3A, B). This population of XCR1-
positive cells also expressed the oligodendrocyte
marker Olig2 thus indicating that these cells were
oligodendrocytes (Fig. 3B). In addition,
immunohistochemical staining of central nervous tissue
revealed XCR1-positive labeling in two distinct areas of
the brainstem, the white matter and the trigeminal
nucleus. In the white matter, XCR1 was specifically co-
localized with Olig2, indicating expression in
oligodendrocytes (Fig. 3A, C); there was no evidence of
XCR1 expression in either microglia or astrocyte glial
cells. In the trigeminal nucleus, XCR1 labeling was
confined to subnucleus caudalis (Vc), with no
expression observed in either interpolaris or oralis.
XCR1 appeared to be localized to nerve terminals in Vc,
in the lamina I and IIo region that contains CGRP-
positive primary afferent terminals (Fig. 3D); however,
when observed using high-magnification confocal
microscopy there was little evidence of colocalization of
XCR1 and CGRP (Fig. 3E). The region of XCR1
labeling was distinct from that for isolectin IB4, seen in
the lamina IIi region of Vc, as illustrated in Fig. 3D, E.
Positive XCR1 labeling was abolished following liquid-
phase pre-absorption of the antibody with its respective
antigen, indicating specificity of the XCR1 antibody
(Fig. 3E).
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XCR1 is expressed in the superficial laminae of
trigeminal subnucleus caudalis and co-exists with
VGlut2
Confocal imaging of Vc in the caudal brainstem sections
of naı¨ve rats revealed intense labeling for XCR1 in the
most superficial layers of Vc (Fig. 4). The diffuse pattern
of labeling was indicative of an axonal or fiber
localization rather than in cell bodies. In double-labeling
studies with the vesicular glutamate transporters VGlut1
or VGlut2 (which mark glutamatergic synaptic
terminals), labeling for XCR1 in Vc showed
colocalization with VGlut2 in superficial layers whereas
VGlut1 staining was distributed to deeper regions with
little evidence of overlap (Fig. 4A–D).
XCL1-mediated induction of c-Fos, pERK and pp38
within trigeminal subnucleus caudalis
Expression of c-Fos, pERK and pp38 was much greater
following direct exposure of brainstem tissue to XCL1,
compared with that in control tissue. As illustrated in
Fig. 5A–C, immunofluorescence for c-Fos, pERK and
pp38 following incubation of the brainstem in vitro for
2 h in aCSF containing XCL1, revealed localized and
profuse labeling in the superficial laminae (laminae I–II)
of Vc. XCL1-induced immunolabeling for c-Fos (118.6
± 11.1 cells/section), pERK (7.29 ± 1.05 cells/section)
and pp38 (mean intensity 134.4 ± 8.9) was significantly
increased when compared with that in matched Vc
tissue incubated with XCL1 in presence of the XCL1
D GAPDH RMN LMN Brainstem 
A PGP 9.5 + XCR1 XCR1 PGP 9.5 
B XCR1 CD45 CD45 + XCR1 
C XCR1 S100 S100 + XCR1 
Fig. 2. XCR1 co-exists with the neuronal marker PGP9.5, the leukocyte common antigen CD45 and the Schwann cell marker S-100 in injured
mental nerve, 3 days following chronic constriction injury (CCI). (A) Immunofluorescent labeling of PGP9.5, highlighting viable nerve axons (green),
XCR1 within the mental nerve (red), and co-localization of XCR1 within PGP9.5-labeled axons of the mental nerve (yellow). Scale bars = 100 lm.
(B) Expression of CD45-positive cells expressing XCR1-like immunoreactivity (yellow) in injured mental nerve. Scale bars = 100 lm. (C) Co-
localization of XCR1 with structures positively labeled with S-100 (yellow). Scale bars = 50 lm. (D) 3 days following CCI, RT–PCR revealed much
higher levels of XCR1 mRNA in injured left mental nerve (LMN) compared with the uninjured right mental nerve (RMN), where mRNA was barely
detectable; XCR1 mRNA was also present in the brainstem.
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Fig. 3. XCR1 is expressed in the trigeminal root and brainstem. (A) Immunofluorescent XCR1 positively labeled cells (red) in the trigeminal root
(red) and co-localized in oligodendrocytes (yellow) in the brainstem. (B) Positive co-localization of XCR1 with oligodendrocyte marker Olig2, in the
central part of the transition zone. (C) XCR1 immunoreactive-positive cells (red) in the white matter of the brainstem, co-localized (yellow) with
Olig2-positive cells (green). (D) XCR1 is expressed in the Vc region of the trigeminal nucleus, showing expression within laminae I and IIo and in the
same region as CGRP, but not in laminae IIi or in the same region as IB4. (E) Following pre-absorption of the XCR1 primary antibody with its
respective antigen, no XCR1 labeling was observed. Confocal analysis showed XCR1 does not co-localize with CGRP- or IB4-labeled fibers. All
scale bars = 50 lm.
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antagonist vMIP-II (44.5 ± 3.0 cells/section [p< 0.001],
2.26 ± 0.31 cells/section [p< 0.01] and mean intensity
84.7 ± 8.7 [p< 0.01], respectively), vMIP-II alone
(57.4 ± 5.6 cells/section [p< 0.01], 0.60 ± 0.29 cells/
section [p< 0.001] and mean intensity 81.6 ± 4.3
[p< 0.01], respectively) or untreated controls incubated
VGlut1 
VGlut1 
A 
B 
VGlut2 
VGlut2 
C 
D 
VGlut1 + XCR1 
VGlut1 + XCR1 
VGlut2 + XCR1 
VGlut2 + XCR1 
XCR1 
XCR1 
XCR1 
XCR1 
Fig. 4. XCR1 immunoreactivity in Vc was found to overlap extensively with the vesicular glutamate transporter 2 (VGlut2). (A–D) Confocal images
of 50-lm transverse sections of brainstem cut caudally from obex. (A, B) Co-localization of XCR1 (red) and VGlut1 (green) in the caudal brainstem.
(C, D) Co-localization of XCR1 (red) and VGlut2 (green) in the caudal brainstem. (B, D) Show enlargement of squared boxes in A and C,
respectively. In (A–D) the single staining for each antibody and the merged image are shown from left to right and double staining appears in yellow.
All scale bars = 100 lm.
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in drug-free aCSF (29.9 ± 7.30 cells/section [p<0.0001],
1.47 ± 0.28 cells/section [p< 0.001] and mean
intensity 73.6 ± 3.90 [p< 0.01], respectively) (Fig. 5D–
F). Since in vitro Vc tissue was co-incubated with TTX,
which effectively uncoupled axonally conducted
excitation, it is likely that expression of c-Fos, pERK and
pp38 was directly induced by XCL1 rather than by
indirect non-specific excitation. Expression of c-Fos,
pERK and pp38 was most pronounced in the superficial
regions of Vc, though it clearly extended to deeper Vc
laminae (laminae III–IV; Fig. 5). Using a double-labeling
protocol that combined c-Fos, pERK and pp38
immunofluorescence with that for the neuronal marker
NeuN, microglial marker Iba1 and astrocyte marker
GFAP, positive labeling for c-Fos, pERK and pp38 was
only colocalized with that for NeuN (Fig. 6).
XCL1 acting via XCR1 increases neuronal excitability
in trigeminal subnucleus caudalis
Functional electrophysiology recordings showed that in
rat brainstem slices bathed in control aCSF for 2 h, a
minimal level of subthreshold spontaneous rhythmic
(4–12 Hz) excitatory activity was recorded within Vc
(Fig. 7A, B). In brainstem slices pre-incubated and
bathed in XCL1 for 2 h, an increased level of ongoing
Fig. 5. XCL1 increases expression of c-Fos, pERK and pp38 in Vc that is blocked by the XCR1 antagonist viral CC chemokine macrophage
inhibitory protein-II (vMIP-II). Distribution of immunolabeling for (A) c-Fos, (B) pERK and (C) pp38 in Vc following a 2-hour incubation with drug-free
aCSF (control), XCL1, XCL1 + vMIP-II, or vMIP-II. c-Fos, pERK and pp38 labeling is localized to the most superficial layers of Vc and is more
pronounced in XCL1-exposed Vc tissue. Incubation of trigeminal brainstem slices with XCL1 (2 h) resulted in an increased activation of c-Fos (D),
pERK (E) and pp38 (F) in the superficial layers of Vc. vMIP-II blocked XCL1-induced activation of c-Fos (D), pERK (E) and pp38 (F) in the superficial
layers of Vc. Numbers in parenthesis indicate animals used. **p< 0.01, ***p< 0.001, ****p< 0.0001 (ANOVA with Dunnett’s post-hoc test). Data
are expressed as the mean ± SEM. Scale bar = 500 lm.
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4–12 Hz neuronal activity was recorded within Vc; this
activity was blocked by the potent XCL1 antagonist
vMIP-II (Fig. 7A, B). Data quantification revealed that
the parameters of peak power amplitude and integrated
power area of the 4–12 Hz rhythmic activity were
significantly increased in Vc of brainstem slices bathed
in XCL1 when compared with control (Fig. 7C; p<
0.01). Compared with control values (expressed as
106 V2) of 0.016 ± 0.001 for power amplitude and
0.087± 0.012 for power area (n=6), the corresponding
values increased to 0.040 ± 0.008 and 0.178 ± 0.038,
respectively (both p< 0.01), in the presence of XCL1
(2 h, n= 6). This low-amplitude subthreshold oscillatory
behavior possessed characteristics similar to those
induced by the epileptogenic drug 4-AP (25 mM), as
previously reported for spinal dorsal horn (Chapman
et al., 2009). The XCL1-induced increases in power
amplitude and power area were blocked by vMIP-II
(0.012±0.002 106V2 and 0.059± 0.009 106V2, respec-
tively [n= 5]; both p< 0.01) (Fig. 7C). Neither vMIP-II
A 
B 
C 
NueN+soF-cNueNsoF-c
NueN+KREpNueNKREp
pp38 NeuN pp38 + NeuN 
Fig. 6. c-Fos, pERK and pp38 are expressed in neuronal cells in Vc. Immunolabeling for c-Fos (A), pERK (B) and pp38 (C) co-localizes with
neuronal marker NeuN in Vc. Representative figures are from brainstem slices incubated for 2 h in aCSF containing TTX plus XCL1 (see Methods)
prior to processing for immunohistochemistry. (A–C) Confocal images of 50-lm transverse sections of brainstem caudal to obex. (A) Co-localization
of c-Fos (red) and NeuN (green) in Vc. (B) Co-localization of pERK (red) and NeuN (green) in Vc. (C) Co-localization of pp38 (red) and NeuN (green)
in Vc. In (A–C) the single staining for each antibody and the merged image are shown from left to right; co-localization appears in yellow.
Scale bars = 10 lm.
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nor XCL1 had an effect on the dominant frequency of
spontaneous rhythmic activity, which remained con-
strained to the 4–12 Hz range (Fig. 7B).
DISCUSSION
This is the first study to identify XCR1 in the trigeminal
system, to demonstrate that XCR1 is upregulated at
sites of nerve injury, and to describe a role for the
XCL1-XCR1 axis in modulating intracellular signaling
and neuronal excitability.
XCR1 is upregulated at sites of nerve injury
We have demonstrated that the expression of XCR1 in
the rat mental nerve is elevated 3 days following CCI,
compared with 11 days post-CCI and sham controls. At
this site XCR1 co-exists with neuronal marker PGP9.5,
leukocyte common antigen CD45, and Schwann cell
marker S-100. The time course of altered XCR1
expression relates closely to that of the development of
spontaneous (ectopic) activity at sites of trigeminal
nerve injury (Bongenhielm and Robinson, 1996, 1998;
Yates et al., 2000). Ectopic activity at these sites plays
a role in the development of pain following nerve injury
(Devor and Seltzer, 1999). A number of modulators of
neuronal excitability show increased expression at trigem-
inal nerve injury sites, including neuropeptides, ion chan-
nels, nitric oxide synthase and TRP channels (Bird et al.,
2002, 2003; Davies et al., 2004, 2006; Biggs et al., 2007),
and other chemokines and their receptors (discussed
below). Many of these molecules have been implicated
in the development of spontaneous activity, but the pre-
cise mechanisms are not yet established. Upregulation
Fig. 7. XCL1 acting via XCR1 increases neuronal excitability in Vc. (A) Exemplar raw data trace from a single trigeminal brainstem slice showing:
low-level spontaneous subthreshold voltage oscillations recorded in Vc in vitro in control aCSF (top trace); enhanced ongoing 4- to 12-Hz oscillatory
activity in a single brainstem slice incubated in XCL1 (0.1 lM, 2 h) (upper middle trace); reduced intensity of XCL1-induced oscillatory activity by co-
incubation of XCL1 and the antagonist vMIP-II (0.1 lM, 2 h) (lower middle trace). (B) Power spectra derived from raw data shown in (A) of low-
amplitude rhythmic oscillations reveal a dominant frequency within 4- to 12-Hz frequency band and enhanced 4- to 12-Hz activity after exposure to
XCL1 that is reduced by vMIP-II. Note that, relative to the drug-free control, MIP-II alone did not enhance baseline oscillatory activity. (C) The peak
power amplitude and power area of the 4- to 12-Hz rhythmic activity was significantly increased within Vc in slices bathed in XCL1 (p< 0.01); this
effect was blocked by vMIP-II. Data are expressed as mean ± SEM and the number of slices used for each is shown in parenthesis on the x-axis
(ANOVA with Dunnett’s post-hoc test).
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of XCR1 in a number of cell types at the injury site could
also implicate the XCL1-XCR1 axis in the development of
ectopic activity, via neural–immune and/or neural–glial
interactions; thus, this axis has potential to contribute to
the development of neuropathic pain.
At the nerve injury site, XCR1 was present in nerve
fibers, CD45-positive leucocytes and Schwann cells.
Other chemokine receptors have also been reported in
a range of cell types in the peripheral nervous system,
and shown to be upregulated following nerve injury. For
example, the CXCL12 receptor CXCR4 has been found
within sciatic nerve fibers where it is partially colocalized
with CGRP-positive axons (Reaux-Le Goazigo et al.,
2012). Increased expression of CXCR4 has been
observed in macrophages following sciatic nerve injury
(Dubovy´ et al., 2007, 2010), and CXCR4 activation con-
tributes to persistent pain via regulating the excitability
of peripheral nociceptive neurons (Yang et al., 2015).
The CCL2 receptor CCR2 is also expressed in macro-
phages – at the injury site and in the DRG following nerve
injury (Abbadie et al., 2003) – and has been implicated in
the development of neuropathic pain. Thus both the
CXCL12-CXCR4 and the CCL2-CCR2 chemokine axes
have been shown to contribute to peripheral mechanisms
of nociception and neuropathic pain. Similarly, altered
expression of XCR1 in neurons and immune cells at sites
of nerve injury indicates the potential of the XCL1-XCR1
axis to influence development of neuropathic pain via a
peripheral mechanism.
XCR1 is expressed in glial cells involved in
myelination
The expression of XCR1 in Schwann cells at the nerve
injury site, and in oligodendrocytes in the trigeminal root
and white matter of the brainstem is of potential interest.
These cells have a well-established role in myelination
but there also is growing evidence that they have an
important role in regulating local immune responses and
can contribute to the development of inflammatory
peripheral neuropathies (Ydens et al., 2013) and a range
of central nervous system (CNS) disorders. Chemokine
expression has been reported in Schwann cells (eg
MCP-1/CCL2) and linked to neuroinflammatory disease
(eg Guillain–Barre´ syndrome) (Orlikowski et al., 2003).
Several chemokine receptors (eg CXCR1, CXCR2,
CXCR3) are expressed in oligodendrocytes and show
increased expression in MS, stroke and amyotrophic lat-
eral sclerosis (Omari et al., 2005), and have been impli-
cated in disorders in which myelin damage is associated
with immune activation in the CNS. The particular associ-
ation between XCR1 and myelinating glia suggests a
potential role for XCR1 in diseases linked with myelination
disorders.
XCR1 is expressed in nerve terminals in the outer
laminae of Vc
In Vc, XCR1 immuno-positive labeling was distributed
most strongly across the outer superficial laminae and
was found only sparsely in deeper laminae. The lack of
clearly labeled cell bodies and the diffuse pattern of
XCR1 immuno-positive staining were suggestive of an
association with axonal arborizations, fibers or local
terminals. In relation to nociceptive primary afferent
terminals, no association or overlap was found between
immunolabeling for IB4-positive terminals and XCR1,
thus excluding a strong association for XCR1 with this
class of non-peptidergic C-afferent. Immuno-positive
staining for both XCR1 and CGRP co-existed within
lamina I and IIo but there was little evidence of clear co-
localization so it is not possible to associate XCR1 with
CGRP-expressing peptidergic C-afferents. Examination
of the expression patterns for either vGlut1 or vGlut2
transporters indicated a clear regional separation with
the highest density of immunolabeling for vGlut1 across
deep laminae whereas vGlut2 was within superficial
laminae, particularly laminae II. Double-immunolabeling
with XCR1 indicated a strong co-localization with vGlut2
but not vGlut1. Thus these data show that XCR1 is
expressed in vGlut2- but not vGlut1-, CGRP-, or IB4-
containing terminals. This is consistent with previous
studies reporting that few vGlut2-containing terminals
express either CGRP or IB4, and that these three
markers are typically expressed in separate populations
of terminals in dorsal horn and Vc (Todd et al., 2003;
Morris et al., 2005; Hegarty et al., 2010). In spinal dorsal
horn, many vGlut2-containing terminals originate from
local glutamatergic interneurons (Todd et al., 2003).
Taken together, this suggests that XCR1 may be
expressed in terminals of A-delta afferents, C-fiber affer-
ents that are non-peptidergic and non-IB4 binding, and/
or within excitatory interneurons. While the presence of
chemokine receptors in the spinal cord and Vc is well doc-
umented, their expression is generally reported in micro-
glia and/or neuronal cell bodies – eg CCR2 (Abbadie,
2005; Zhang et al., 2012) and CX3CR1 (Lindia et al.,
2005; Kiyomoto et al., 2013). Thus the pattern of labeling
for XCR1 appears somewhat different to that reported for
other chemokine receptors. The only previous study to
report XCR1 expression in the CNS (Zychowska et al.,
2016) describes increased levels in a mouse model of
type 1 diabetes (streptozotocin model). The study
reported XCR1 to be present in neuronal cell bodies in
the lumbar spinal cord but did not provide further detail
as to the location of the XCR1-containing cell bodies.
XCL1 induces physiological and cellular indices of
central sensitization in Vc
The chemokine XCL1 is produced in infectious and
inflammatory processes but its role in mechanisms of
central sensitization in Vc is unknown. Two different
in vitro methodologies indicated that XCL1 could
potentially and substantially drive central sensitization
within trigeminal dorsal horn circuitry. Firstly, c-Fos,
pERK and pp38 immunolabeling localized to laminae I–
II of Vc was significantly increased in trigeminal
brainstem tissue exposed to XCL1. The colocalization of
these markers with neurons in Vc provides further
evidence that XCR1 is expressed on terminals of Vc
interneurons (discussed above). Expression of c-Fos,
pERK and pp38 in Vc is used widely as a marker of
central sensitization in models of persistent orofacial
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pain (Anton et al., 1991; Hathaway et al., 1995; Worsley
et al., 2014) and, in spinal cord, expression of these mark-
ers is induced by noxious stimulation or tissue injury (Hunt
et al., 1987; Gao and Ji, 2009; Ji et al., 2009). Secondly,
XCL1 directly and significantly enhanced spontaneous
rhythmic 4–12 Hz low-amplitude voltage oscillations
recorded extracellularly in the Vc region. Spontaneous
subthreshold neuronal activity of this type has been char-
acterized in the spinal dorsal horn (Chapman et al., 2009;
Kay et al., 2016). This behavior can be induced by 4-
aminopyridine (4-AP), a convulsant used in a model of
spinal hyperexcitability (Ruscheweyh and Sandku¨hler,
2003). These electrophysiological functional data reveal
that application of XCL1 induces increased spontaneous
low-threshold activity, which may represent a form of
hyperexcitability within the Vc nociceptive circuitry. Spon-
taneously hyperactive neuronal discharges are an estab-
lished characteristic of chronic pain and a known driver for
central sensitization (Suzuki and Dickenson, 2006).
Enhanced expression of molecular markers of pain and
increased neuronal excitability were both significantly
attenuated by the specific XCR1 antagonist vMIP-II,
thereby directly linking these effects of XCL1 to its cog-
nate receptor. There is evidence that application of
CXCL12, CCL2 or CX3CL1 to the spinal cord (intrathe-
cally) and/or Vc (intracisternally) produces behavioral
changes such as mechanical allodynia and thermal
hyperalgesia (Abbadie 2005; Kiyomoto et al., 2013), indi-
cating a role for these chemokines in modulation of cen-
tral nociceptive processing. The data we present here
infer a putative role for the XCL1-XCR1 axis in central
modulation of nociceptive processing and the develop-
ment of central sensitization in the trigeminal pain system.
However, further studies of the effects of XCL1 on Vc
synaptic excitation and sensory afferent inputs will be
required to confirm this.
The data in this paper were obtained using different
strains of rats, which reflect the working practices of the
two labs, our established protocols and the specific
requirements for the techniques used. For example, the
slice preparation experiments are most reliable in young
animals (65–80 g), whereas the CCI injury requires the
use of larger animals (225–250 g). However, of
particular relevance in relation to this is that the laminar
distribution of XCR1 in Vc and that of XCL1-mediated
induction of c-Fos, pERK and pp38 across these
variations are the same, thus demonstrating further the
robust nature of the data, with reproducibility across
strains and ages.
In conclusion, we have demonstrated that XCR1 is
upregulated at sites of trigeminal nerve injury with a
time course that correlates with the development of
spontaneous activity at these sites. In Vc, XCR1
immunoreactivity is present in the outer laminae in a
manner consistent with XCR1 expression in terminals of
A-delta afferents, C-fiber afferents that are non-
peptidergic and non-IB4 binding, and/or excitatory
interneurons. Exposure of trigeminal brainstem tissue to
XCL1 induces expression of c-Fos, pERK and pp38
immunolabeling in laminae I–II of Vc, and induces
increased spontaneous low-threshold activity indicative
of hyperexcitability within the Vc nociceptive circuitry.
Taken together the data from this study provide the first
evidence that the XCL1-XCR1 axis may play a role
within peripheral and central trigeminal pain pathways,
and indicate that this axis may provide a potential target
for novel analgesics.
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